We performed targeted bisulfite sequencing to discover specific methylation changes in 14 AML samples of diverse clinical and genetic background versus a pool of CD34+ healthy control cells (see Table 1 for patients’ characteristics). This evidence concerns the gene CD34 and acute myeloid leukemia.